OATP1B型的运输功能是芳酶抑制剂相关关节痛敏感性的决定因素
Hanieh Taheri1, Yang Li1, Kevin M Huang1
1Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, Ohio.
Cancer research communications
|March 10, 2025
概括
芳香酶抑制剂 (AIs) 由于药理动力学变异性,可能导致关节疼痛. 肝脏OATP1B转运体影响AI水平,转运体活性降低与乳腺癌患者的AI相关关节痛增加有关.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
背景情况:
- 芳香酶抑制剂 (AIs) 是绝经后妇女患有激素受体阳性乳腺癌的标准辅助疗法.
- 对于药物抑制剂,存在显著的个人间的药物动力学变异性,可能会影响治疗疗效和毒性.
- 人工智能相关的关节痛是一种常见的,使人虚弱的副作用,病因不明确.
研究的目的:
- 调查肝脏吸收载体在AIs的药理动力学变异性中的作用.
- 确定OATP1B载体是否参与AI消除和AI相关关节痛的发展.
- 探索传送生物标志物的潜力,以预测和减轻人工智能相关的毒性.
主要方法:
- 进行了in silico,in vitro,in vivo和人类研究.
- 确定了OATP1B1和OATP1B3 (人类) 和Oatp1b2 (小鼠) 作为AI消除的关键传递体.
- 评估了肝脏OATP1B输送活性与患者的AI相关关节痛之间的关联.
主要成果:
- 小鼠的遗传缺陷导致AI血水平升高,关节痛增加.
- 乳腺癌患者肝脏OATP1B型转运体活性较低与AI相关的关节痛增加相关.
- 这些发现确定了消除人工智能的速度限制步骤.
结论:
- 肝脏OATP1B载体在AI的药理动力学和AI相关关节痛的表现中发挥着关键作用.
- 载体生物标志物可能会预测对人工智能诱导的关节痛的易感性.
- 准运输者活动可能提供一个策略来减轻这种常见的毒性.
相关概念视频
Carrier-Mediated Transport
228
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
228
Nonlinear Pharmacokinetics: Role of Transporters
26
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
26
ABC Transporters: Exporter
4.1K
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
4.1K
Allosteric Proteins-ATCase
5.6K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
5.6K
Hepatic Drug Clearance: Role of Transporters
31
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
31
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
23
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
23


